2-(1-哌嗪)-苯并咪唑 | 57260-68-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 2-(1-哌嗪)-苯并咪唑
• 英文名称: 2-(1-piperazinyl)-1H-benzimidazole
• 英文别名: 2-(piperazin-1-yl)benzimidazole；2-(piperazin-1-yl)-1H-benzimidazole；2-(piperazin-1-yl)-1H-benzo[d]imidazole；2-piperazin-1-yl-1H-benzoimidazole；2-piperazin-1-yl-1H-benzimidazole
• CAS: 57260-68-1
• 化学式: C₁₁H₁₄N₄
• mdl: MFCD01075239
• 分子量: 202.259
• InChiKey: NZXGDKLTTHIYTB-UHFFFAOYSA-N

物化性质

• 沸点：
  409.0±55.0 °C(Predicted)
• 密度：
  1.237±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  44
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-(1-哌嗪)-苯并咪唑 在 氢气 、 镍 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 ethyl 6-amino-7-[4-(1H-benzimidazol-2-yl)piperazin-1-yl]-1-methyl-4-oxoquinoline-3-carboxylate
  参考文献：
  名称：

  Structure Modifications of 6-Aminoquinolones with Potent Anti-HIV Activity

  摘要：

  We have recently discovered that 6-aminoquinolone derivatives could be valid leads for the development of new anti-HIV agents because of their new and diversified mode of action. In fact, studies carried out on the lead WM5 showed that this derivative is able to inhibit the Tat-mediated long terminal repeat driven transcription, an essential step in the HIV-1 replication cycle. Thus, starting from lead WM5, we performed the design and synthesis of an enlarged series of 6-aminoquinolones, which permitted some very potent anti-HIV 6-amino derivatives to be obtained and the structure-activity relationship to be delineated. Some derivatives, 26c, 26e, 26i, and 26j, proved to be highly effective in inhibiting HIV replication at 50% inhibitory concentration in the range of 0.0087-0.7 mug/mL in MT-4, PBMCs and CEM cell lines coupled with positive selectivity indexes that reach values higher than 1000 on CEM cell lines for compounds 26e and 26i. Time-of-addition experiments clearly confirm that the new, potent 6-aminoquinolones interact at a postintegration step in the replication cycle of HIV.

  DOI：

  10.1021/jm049721p
• 作为产物：
  描述：

  2-羟基苯并咪唑 在 三氟乙酸 、 三氯氧磷 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 8.0h， 生成 2-(1-哌嗪)-苯并咪唑
  参考文献：
  名称：

  From Cells to Mice to Target: Characterization of NEU-1053 (SB-443342) and Its Analogues for Treatment of Human African Trypanosomiasis

  摘要：

  Human African trypanosomiasis is a neglected tropical disease that is lethal if left untreated. Existing therapeutics have limited efficacy and severe associated toxicities. 2-(2-(((3-((1H-Benzo[d]imidazol-2-yl)amino)propyl)amino)methyl)-4,6-dichloro-1H-indol-1-yl)ethan-1-ol (NEU-1053) has recently been identified from a high-throughput screen of >42,000 compounds as a highly potent and fast-acting trypanocidal agent capable of curing a bloodstream infection of Trypanosoma brucei in mice. We have designed a library of analogues to probe the structureactivity relationship and improve the predicted central nervous system (CNS) exposure of NEU-1053. We report the activity of these inhibitors of T. brucei, the efficacy of NEU-1053 in a murine CNS model of infection, and identification of the target of NEU-1053 via X-ray crystallography.

  DOI：

  10.1021/acsinfecdis.6b00202

文献信息

• 2-Benzazolyl-4-Piperazin-1-Ylsulfonylbenzenecarbohydroxamic Acids as Novel Selective Histone Deacetylase-6 Inhibitors with Antiproliferative Activity
  作者：Lei Wang、Marina Kofler、Gerald Brosch、Jelena Melesina、Wolfgang Sippl、Elisabeth D. Martinez、Johnny Easmon

  DOI：10.1371/journal.pone.0134556

  日期：——

  e ring was replaced by the isosteric heterocycles benzimidazole, benzoxazole, and benzothiazole and the position of the hydroxamic acid substituent on the phenyl ring was varied. Whereas compounds bearing a para substituted hydroxamic acid (9a-d) were active HDAC inhibitors, the meta substituted analogues (8a-d) were appreciably inactive. Compounds 9a-d selectively inhibited HDAC6 (IC50 = 0.1-1.0 μM)

  我们已经在建立的基于细胞的测定法中筛选了我们的化合物集合，该测定法测量表观遗传沉默的转基因的去阻抑，即基因座去阻抑测定。该筛选导致鉴定出4- [4-（1-（甲基苯并咪唑-2-基）哌嗪-1-基]磺酰基苯碳氧肟酸（9b）作为抑制HDAC1的活性物质。在初始结构活性关系研究中，1-甲基苯并咪唑环被等位杂环苯并咪唑，苯并恶唑和苯并噻唑取代，并且异羟肟酸取代基在苯环上的位置也有所变化。带有对位取代的异羟肟酸（9a-d）的化合物是活性HDAC抑制剂，而间位取代的类似物（8a-d）则无活性。与HDAC1（IC50 = 0）相比，化合物9a-d选择性抑制HDAC6（IC50 = 0.1-1.0μM）。而且，与患者匹配的正常细胞相比，也有选择性地抑制了肺癌细胞（9-6μM）的生长。与对照组相比，该化合物在S期诱导细胞周期停滞，而细胞凋亡的诱导则可忽略。分子模型研究发现，9a-d与HDAC6相互作用的MM-G
• Oxazolone derivatives and uses thereof
  申请人：Syntex (U.S.A.) LLC

  公开号：US06355641B1

  公开（公告）日：2002-03-12

  This invention relates to compounds which are generally alpha1B-receptor antagonists, and which are represented by Formula (I): wherein X, Y, and R1 are as defined in the specification, or individual isomers or racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, and methods for their use as therapeutic agents.

  这项发明涉及一般为α1B-受体拮抗剂的化合物，其由式(I)所代表： 其中X、Y和R1如规范中所定义，或者是各个异构体或消旋或非消旋异构体的混合物，或其药学上可接受的盐或溶剂。该发明还涉及含有这种化合物的药物组合物，以及它们作为治疗剂的使用方法。
• Design, Synthesis, and Binding Affinities of Potential Positron Emission Tomography (PET) Ligands for Visualization of Brain Dopamine D₃ Receptors
  作者：Marcello Leopoldo、Enza Lacivita、Paola De Giorgio、Nicola A. Colabufo、Mauro Niso、Francesco Berardi、Roberto Perrone

  DOI：10.1021/jm050734s

  日期：2006.1.1

  report the synthesis of compounds structurally related to the high-affinity dopamine D(3) receptor ligand N-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]-7-methoxy-2-benzofurancarboxami de (1). All compounds were specifically designed as potential PET radioligands for brain D(3) receptors visualization, having lipophilicity within a range for high brain uptake and weak nonspecific binding (2 < ClogP

  我们在这里报告了与高亲和力多巴胺D（3）受体配体N- [4- [4-（4-（2,3-二氯苯基）哌嗪-1-基]丁基] -7-甲氧基-2相关的化合物的合成-苯并呋喃carboxami de（1）。所有化合物均经过专门设计，可作为潜在的PET放射性配体用于大脑D（3）受体的可视化，具有一定的亲脂性，可在一定范围内实现高脑摄取和弱非特异性结合（2
• Gonadotropin releasing hormone receptor antagonists
  申请人：Garrick Michael Lloyd

  公开号：US20060019965A1

  公开（公告）日：2006-01-26

  The present invention relates to Gonadotropin Releasing Hormone (“GnRH”) (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists.

  本发明涉及促性腺激素释放激素（“GnRH”）（也称为促黄体生成激素释放激素）受体拮抗剂。
• Sulfonamide compounds with pharmaceutical activity
  申请人：SmithKline Beecham p.l.c.

  公开号：US20030130275A1

  公开（公告）日：2003-07-10

  The invention relates to novel sulphonamide compounds having 5-HT 7 antagonist activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.

  这项发明涉及具有5-HT7拮抗活性的新型磺胺基化合物，其制备方法，含有它们的组合物以及它们在治疗中枢神经系统和其他疾病中的用途。